Marc K. Walton

Botulinum toxin type A injections: Adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases

Timothy R. Coté, Aparna Mohan, Jacquelyn A. Polder et al. · Journal of the American Academy of Dermatology · 2005 · 362 citations

Medicine, Toxicology, Hypersensitivity +7

Clinical Outcome Assessments: Conceptual Foundation—Report of the ISPOR Clinical Outcomes Assessment – Emerging Good Practices for Outcomes Research Task Force

Marc K. Walton, John H. Powers, Jeremy Hobart et al. · Value in Health · 2015 · 318 citations · Full text

Pharmacy, Clinical Sciences, Outcomes Research +13

Clinician-Reported Outcome Assessments of Treatment Benefit: Report of the ISPOR Clinical Outcome Assessment Emerging Good Practices Task Force

John H. Powers, Donald L. Patrick, Marc K. Walton et al. · Value in Health · 2017 · 180 citations · Full text

Pharmacy, Health Policy, Good Clinical Practice +13

The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design

Munyaradzi Dimairo, Philip Pallmann, James Wason et al. · BMJ · 2020 · 158 citations · Full text

Public Health, Biostatistics, Evidence-based Practice +16

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report

Sophie Paczesny, Frances T. Hakim, Joseph Pidala et al. · Biology of Blood and Marrow Transplantation · 2015 · 143 citations · Full text

Medicine, Hematology, Immunology +16